Yahoo Web Search

Search results

    • Q1 2024 AIM ImmunoTech Inc Earnings Call

      Thomson Reuters StreetEvents via Yahoo Finance· 4 days ago

      The Phase 1 portion of the trial is a 3-in-3 escalation design with fixed durvalumab dosing and escalating Ampligen...response rate of 45%. When you compare this to the ORR or objective response ...